Acura Pharmaceuticals (STU:HD4B) Short Interest


STU:HD4B Acura Pharmaceuticals Inc STU:HD4B
16 GF Score
Price €0.20
View Full Analysis

What is Acura Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:HD4B vs VFRM, THCT, CBGL: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acura Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Short Interest falls into.


STU:HD4B
16GF Score
Acura Pharmaceuticals Inc STU:HD4B
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for STU:HD4B

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price